Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, development, and commercialization of life-changing therapeutics for people living with neurological and psychiatric disorders. The company's mission is to deliver innovative medicines by leveraging its deep expertise in ion channel biology and genetics. Headquartered in Burnaby, British Columbia, Canada, Xenon also maintains offices in Vancouver, British Columbia, and Boston, Massachusetts.

Xenon's core business revolves around ion channel science, specifically targeting potassium and sodium channels to address conditions such as epilepsy, major depressive disorder (MDD), bipolar depression (BPD), and pain. Its lead investigational candidate, azetukalner (formerly XEN1101), is a novel Kv7 potassium channel opener currently in Phase 3 clinical trials for focal epilepsy, primary generalized tonic-clonic seizures, MDD, and BPD. The company's pipeline also includes early-stage programs like XEN1120 and XEN1701 in Phase 1 development for pain, alongside other preclinical candidates targeting various ion channels for neurological and psychiatric indications.

As a publicly traded entity on NASDAQ under the ticker XENE, Xenon Pharmaceuticals is led by President and CEO Ian C. Mortimer. The company recently presented positive Phase 3 X-TOLE2 study results and 48-month long-term data for azetukalner in focal onset seizures at the 2026 AAN Annual Meeting in April. In March 2026, Xenon closed an upsized public offering, raising $747.5 million. The company is scheduled to report its Q1 2026 financial results on May 7, 2026, and will be participating in several investor conferences throughout May.